<code id='12A2F6107C'></code><style id='12A2F6107C'></style>
    • <acronym id='12A2F6107C'></acronym>
      <center id='12A2F6107C'><center id='12A2F6107C'><tfoot id='12A2F6107C'></tfoot></center><abbr id='12A2F6107C'><dir id='12A2F6107C'><tfoot id='12A2F6107C'></tfoot><noframes id='12A2F6107C'>

    • <optgroup id='12A2F6107C'><strike id='12A2F6107C'><sup id='12A2F6107C'></sup></strike><code id='12A2F6107C'></code></optgroup>
        1. <b id='12A2F6107C'><label id='12A2F6107C'><select id='12A2F6107C'><dt id='12A2F6107C'><span id='12A2F6107C'></span></dt></select></label></b><u id='12A2F6107C'></u>
          <i id='12A2F6107C'><strike id='12A2F6107C'><tt id='12A2F6107C'><pre id='12A2F6107C'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:focus    Page View:83356
          Judge's gavel
          Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

          WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

          Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

          advertisement

          Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Wikipedia

          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more
          J&J to buy cancer drug developer Ambrx Biopharma
          J&J to buy cancer drug developer Ambrx Biopharma

          AP/RichardDrewJohnson&JohnsonsaidMondaythatitwouldpurchaseAmbrxBiopharmafornearly$2billion,picki

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          Burning questions for the 2024 JPM Healthcare Conference

          AlexHogan/STATTheJ.P.MorganHealthcareConferenceisuponus,bringingitsfreneticmeetings,crowdedhallways,